Go Pro

James Molloy Analyst Performance

Analyst at Alliance Global Partners

James Molloy is a stock analyst at Alliance Global Partners focused in the healthcare sector, covering 21 publicly traded companies. Over the past year, James Molloy has issued 2 stock ratings, including and buy recommendations. While full access to James Molloy's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights James Molloy's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
25 Last 11 Years
Buy Recommendations
92.00% 23 Buy Ratings
Companies Covered
21 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy16.0%4 ratings
Buy76.0%19 ratings
Hold8.0%2 ratings
Sell0.0%0 ratings

Out of 25 total stock ratings issued by James Molloy at Alliance Global Partners, the majority (76.0%) have been Buy recommendations, followed by 16.0% Strong Buy and 8.0% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
85.7% of companies on NASDAQ
18 companies
NYSEAMERICAN
14.3% of companies on NYSEAMERICAN
3 companies

James Molloy, an analyst at Alliance Global Partners, currently covers 21 companies listed on NASDAQ and NYSEAMERICAN, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
19 companies
90.5%
Energy
2 companies
9.5%

James Molloy of Alliance Global Partners specializes in stock coverage within the Healthcare sector, with additional focus on Energy companies.

Coverage Industries

IndustryPercentage
PHARMACEUTICALS
9 companies
42.9%
BIOTECHNOLOGY
8 companies
38.1%
HEALTHCARE EQUIPMENT & SUPPLIES
2 companies
9.5%
OIL, GAS & CONSUMABLE FUELS
2 companies
9.5%

James Molloy's Ratings History at Alliance Global Partners

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
8/3/2026Initiated Coverage$3.34$11.00Buy
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
6/8/2026Initiated Coverage$2.92$18.00Buy
Soligenix Inc. stock logo
SNGX
Soligenix
7/16/2025Lower Price Target$1.30$6.00Buy
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
5/22/2025Reiterated Rating$1.15Buy
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
4/15/2025Lower Price Target$26.75$212.50Buy
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
3/6/2025Reiterated Rating$0.31$3.50Buy
BioCardia, Inc. stock logo
BCDA
BioCardia
1/30/2025Upgrade$2.47Strong-Buy
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
1/24/2025Upgrade$0.10Strong-Buy
Intensity Therapeutics Inc. stock logo
INTS
Intensity Therapeutics
1/13/2025Initiated Coverage$53.69$212.50Buy
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
12/9/2024Initiated Coverage$17.67$35.00Buy
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
11/11/2024Initiated Coverage$48.75$375.00Buy
IceCure Medical Ltd. stock logo
ICCM
IceCure Medical
11/1/2024Upgrade$0.85Strong-Buy
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
11/1/2024Downgrade$0.57Hold
INmune Bio, Inc. stock logo
INMB
INmune Bio
10/21/2024Initiated Coverage$5.11$20.00Buy
Scilex Holding Company stock logo
SCLX
Scilex
10/16/2024Initiated Coverage$28.28$490.00Buy
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
8/21/2024Upgrade$3.48Strong-Buy